Premium
Inhibition of mouse mammary carcinoma development with doxorubicin in liposomes
Author(s) -
Vaage Jan,
Working Peter,
Uster Paul
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980105)75:1<158::aid-ijc24>3.0.co;2-b
Subject(s) - mammary carcinoma , doxorubicin , liposome , mammary gland , medicine , carcinoma , chemotherapy , ratón , cancer research , pharmacology , chemistry , cancer , breast cancer , biochemistry
Abstract Monthly treatments with intravenous doxorubicin encapsulated in long circulating, sterically stabilized liposomes delayed the appearance of primary mammary carcinomas and reduced the final incidence from 49 in 50 untreated mice to 46 in 87 treated mice. No toxic side effects of the treatments were observed. Int. J. Cancer 75:158–159, 1998.© 1998 Wiley‐Liss, Inc.